More MPA (35.7% in Group 1 and 36.3% in Group 2) than GPA patients (18.7% in Group 1 and 15.4% in Group 2) suffered from renal failure at inclusion and over the four years prior to inclusion (p < 0.0001) (Supplement Fig. 1). This evidence concerns the gene GYPA and kidney failure.